Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK
Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )
5 Oct 2016

Small cell lung cancer: Q & A

Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson
Small cell lung cancer: Q & A ( Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson )
5 Oct 2016

Small cell lung cancer: New therapies

Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK
Small cell lung cancer: New therapies ( Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK )
5 Oct 2016

Small cell lung cancer: Current standards of care

Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK
Small cell lung cancer: Current standards of care ( Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK )
5 Oct 2016

Maintenance in NSCLC: Q & A

Dr Besse and Dr Bhosle
Maintenance in NSCLC: Q & A ( Dr Besse and Dr Bhosle )
5 Oct 2016

Maintenance in NSCLC: Arguments for

Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK
Maintenance in NSCLC: Arguments for ( Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016

Maintenance in NSCLC: Arguments against

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France
Maintenance in NSCLC: Arguments against ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )
5 Oct 2016

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK
We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Prof Gordon McVie - King's College London, London, UK
We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )
5 Oct 2016

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie
Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )
5 Oct 2016

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada
Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )
5 Oct 2016

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng
Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )
5 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation